1 2889 132 GAIN-OF-FUNCTION STAT1 MUTATIONS IMPAIR STAT3 ACTIVITY IN PATIENTS WITH CHRONIC MUCOCUTANEOUS CANDIDIASIS (CMC). SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) TRIGGERED PRODUCTION OF TH-17 CYTOKINES MEDIATES PROTECTIVE IMMUNITY AGAINST FUNGI. MUTATIONS AFFECTING THE STAT3/INTERLEUKIN 17 (IL-17) PATHWAY CAUSE SELECTIVE SUSCEPTIBILITY TO FUNGAL (CANDIDA) INFECTIONS, A HALLMARK OF CHRONIC MUCOCUTANEOUS CANDIDIASIS (CMC). IN PATIENTS WITH AUTOSOMAL DOMINANT CMC, WE AND OTHERS PREVIOUSLY REPORTED DEFECTIVE TH17 RESPONSES AND UNDERLYING GAIN-OF-FUNCTION (GOF) STAT1 MUTATIONS, BUT HOW THIS AFFECTS STAT3 FUNCTION LEADING TO DECREASED IL-17 IS UNCLEAR. WE ALSO ASSESSED HOW GOF-STAT1 MUTATIONS AFFECT STAT3 ACTIVATION, DNA BINDING, GENE EXPRESSION, CYTOKINE PRODUCTION, AND EPIGENETIC MODIFICATIONS. WE EXCLUDED IMPAIRED STAT3 PHOSPHORYLATION, NUCLEAR TRANSLOCATION, AND SEQUESTRATION OF STAT3 INTO STAT1/STAT3 HETERODIMERS AND CONFIRM SIGNIFICANTLY REDUCED TRANSCRIPTION OF STAT3-INDUCIBLE GENES (RORC/IL-17/IL-22/IL-10/C-FOS/SOCS3/C-MYC) AS LIKELY UNDERLYING MECHANISM. STAT BINDING TO THE HIGH AFFINITY SIS-INDUCIBLE ELEMENT WAS INTACT BUT BINDING TO AN ENDOGENOUS STAT3 DNA TARGET WAS IMPAIRED. REDUCED STAT3-DEPENDENT GENE TRANSCRIPTION WAS REVERSED BY INHIBITING STAT1 ACTIVATION WITH FLUDARABINE OR ENHANCING HISTONE, BUT NOT STAT1 OR STAT3 ACETYLATION WITH HISTONE DEACETYLASE (HDAC) INHIBITORS TRICHOSTATIN A OR ITF2357. SILENCING HDAC1, HDAC2, AND HDAC3 INDICATED A ROLE FOR HDAC1 AND 2. REDUCED STAT3-DEPENDENT GENE TRANSCRIPTION UNDERLIES LOW TH-17 RESPONSES IN GOF-STAT1 CMC, WHICH CAN BE REVERSED BY INHIBITING ACETYLATION, OFFERING NOVEL TARGETS FOR FUTURE THERAPIES. 2015 2 3781 43 INTERFERON SIGNATURE IN PATIENTS WITH STAT1 GAIN-OF-FUNCTION MUTATION IS EPIGENETICALLY DETERMINED. STAT1 GAIN-OF-FUNCTION (GOF) VARIANTS LEAD TO DEFECTIVE TH17 CELL DEVELOPMENT AND CHRONIC MUCOCUTANEOUS CANDIDIASIS (CMC), BUT FREQUENTLY ALSO TO AUTOIMMUNITY. STIMULATION OF CELLS WITH STAT1 INDUCING CYTOKINES LIKE INTERFERONS (IFN) RESULT IN HYPERPHOSPHORYLATION AND DELAYED DEPHOSPHORYLATION OF GOF STAT1. HOWEVER, THE MECHANISM HOW THE DELAYED DEPHOSPHORYLATION EXACTLY CAUSES THE INCREASED EXPRESSION OF STAT1-DEPENDENT GENES, AND HOW THE INTRACELLULAR SIGNAL TRANSDUCTION FROM CYTOKINE RECEPTORS IS AFFECTED, REMAINS UNKNOWN. IN THIS STUDY WE SHOW THAT THE CIRCULATING LEVELS OF IFN-ALPHA WERE NOT PERSISTENTLY ELEVATED IN STAT1 GOF PATIENTS. NEVERTHELESS, THE EXPRESSION OF INTERFERON SIGNATURE GENES WAS EVIDENT EVEN IN THE PATIENT WITH LOW OR UNDETECTABLE SERUM IFN-ALPHA LEVELS. CHROMATIN IMMUNOPRECIPITATION (CHIP) EXPERIMENTS REVEALED THAT THE ACTIVE CHROMATIN MARK TRIMETHYLATION OF LYSINE 4 OF HISTONE 3 (H3K4ME3), WAS SIGNIFICANTLY ENRICHED IN AREAS ASSOCIATED WITH INTERFERON-STIMULATED GENES IN STAT1 GOF CELLS IN COMPARISON TO CELLS FROM HEALTHY DONORS. THIS SUGGESTS THAT THE CHROMATIN BINDING OF GOF STAT1 VARIANT PROMOTES EPIGENETIC CHANGES COMPATIBLE WITH HIGHER GENE EXPRESSION AND ELEVATED REACTIVITY TO TYPE I INTERFERONS, AND POSSIBLY PREDISPOSES FOR INTERFERON-RELATED AUTOIMMUNITY. THE RESULTS ALSO SUGGEST THAT EPIGENETIC REWIRING MAY BE RESPONSIBLE FOR TREATMENT FAILURE OF JANUS KINASE 1/2 (JAK1/2) INHIBITORS IN CERTAIN PATIENTS. 2019 3 1303 40 DEFECTIVE TRAINED IMMUNITY IN PATIENTS WITH STAT-1-DEPENDENT CHRONIC MUCOCUTANEAOUS CANDIDIASIS. PATIENTS WITH SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION-1 (STAT1)-DEPENDENT CHRONIC MUCOCUTANEOUS CANDIDIASIS (CMC) AND PATIENTS WITH STAT3-DEPENDENT HYPER-IMMUNOGLOBULIN (IG)E SYNDROME (HIES) DISPLAY DEFECTS IN T HELPER TYPE 17 (TH17) CYTOKINE PRODUCTION CAPACITY. DESPITE THIS SIMILAR IMMUNE DEFECT IN TH17 FUNCTION, THEY SHOW IMPORTANT DIFFERENCES IN THE TYPE OF INFECTIONS TO WHICH THEY ARE SUSCEPTIBLE. RECENTLY, OUR GROUP REPORTED DIFFERENTIAL REGULATION OF STAT-1 AND STAT-3 TRANSCRIPTION FACTORS DURING EPIGENETIC REPROGRAMMING OF TRAINED IMMUNITY, AN IMPORTANT HOST DEFENCE MECHANISM BASED ON INNATE IMMUNE MEMORY. WE THEREFORE HYPOTHESIZED THAT STAT1 AND STAT3 DEFECTS HAVE DIFFERENT EFFECTS ON TRAINED IMMUNITY, AND THIS MAY PARTLY EXPLAIN THE DIFFERENCES BETWEEN CMC AND HIES REGARDING THE SUSCEPTIBILITY TO INFECTIONS. INDEED, WHILE TRAINED IMMUNITY WAS NORMALLY INDUCED IN CELLS ISOLATED FROM PATIENTS WITH HIES, THE INDUCTION OF INNATE TRAINING WAS DEFECTIVE IN CMC PATIENTS. THIS DEFECT WAS SPECIFIC FOR TRAINING WITH CANDIDA ALBICANS, THE MAIN PATHOGEN ENCOUNTERED IN CMC, AND IT INVOLVED A TYPE II INTERFERON-DEPENDENT MECHANISM. THESE FINDINGS DESCRIBE THE ROLE OF STAT-1 FOR THE INDUCTION OF TRAINED IMMUNITY, AND MAY CONTRIBUTE TO THE UNDERSTANDING OF THE DIFFERENCES IN SUSCEPTIBILITY TO INFECTION BETWEEN CMC AND HIES PATIENTS. THIS STUDY COULD ALSO PROVIDE DIRECTIONS FOR PERSONALIZED IMMUNOTHERAPY IN PATIENTS SUFFERING FROM THESE IMMUNODEFICIENCIES. 2015 4 6767 27 ZNF382 CONTROLS MOUSE NEUROPATHIC PAIN VIA SILENCER-BASED EPIGENETIC INHIBITION OF CXCL13 IN DRG NEURONS. NERVE INJURY-INDUCED CHANGES OF GENE EXPRESSION IN DORSAL ROOT GANGLION (DRG) ARE CRITICAL FOR NEUROPATHIC PAIN GENESIS. HOWEVER, HOW THESE CHANGES OCCUR REMAINS ELUSIVE. HERE WE REPORT THE DOWN-REGULATION OF ZINC FINGER PROTEIN 382 (ZNF382) IN INJURED DRG NEURONS AFTER NERVE INJURY. RESCUING THIS DOWN-REGULATION ATTENUATES NOCICEPTIVE HYPERSENSITIVITY. CONVERSELY, MIMICKING THIS DOWN-REGULATION PRODUCES NEUROPATHIC PAIN SYMPTOMS, WHICH ARE ALLEVIATED BY C-X-C MOTIF CHEMOKINE 13 (CXCL13) KNOCKDOWN OR ITS RECEPTOR CXCR5 KNOCKOUT. MECHANISTICALLY, AN IDENTIFIED CIS-ACTING SILENCER AT DISTAL UPSTREAM OF THE CXCL13 PROMOTER SUPPRESSES CXCL13 TRANSCRIPTION VIA BINDING TO ZNF382. BLOCKING THIS BINDING OR GENETICALLY DELETING THIS SILENCER ABOLISHES THE ZNF382 SUPPRESSION ON CXCL13 TRANSCRIPTION AND IMPAIRS ZNF382-INDUCED ANTINOCICEPTION. MOREOVER, ZNF382 DOWN-REGULATION DISRUPTS THE REPRESSIVE EPIGENETIC COMPLEX CONTAINING HISTONE DEACETYLASE 1 AND SET DOMAIN BIFURCATED 1 AT THE SILENCER-PROMOTER LOOP, RESULTING IN CXCL13 TRANSCRIPTIONAL ACTIVATION. THUS, ZNF382 DOWN-REGULATION IS REQUIRED FOR NEUROPATHIC PAIN LIKELY THROUGH SILENCER-BASED EPIGENETIC DISINHIBITION OF CXCL13, A KEY NEUROPATHIC PAIN PLAYER, IN DRG NEURONS. 2021 5 1166 29 CONTRIBUTION OF DNMT1 TO NEUROPATHIC PAIN GENESIS PARTIALLY THROUGH EPIGENETICALLY REPRESSING KCNA2 IN PRIMARY AFFERENT NEURONS. EXPRESSIONAL CHANGES OF PAIN-ASSOCIATED GENES IN PRIMARY SENSORY NEURONS OF DRG ARE CRITICAL FOR NEUROPATHIC PAIN GENESIS. DNA METHYLTRANSFERASE (DNMT)-TRIGGERED DNA METHYLATION SILENCES GENE EXPRESSION. WE SHOW HERE THAT DNMT1, A CANONICAL MAINTENANCE METHYLTRANSFERASE, ACTS AS THE DE NOVO DNMT AND IS REQUIRED FOR NEUROPATHIC PAIN GENESIS LIKELY THROUGH REPRESSING AT LEAST DRG KCNA2 GENE EXPRESSION IN MALE MICE. PERIPHERAL NERVE INJURY UPREGULATED DNMT1 EXPRESSION IN THE INJURED DRG THROUGH THE TRANSCRIPTION FACTOR CAMP RESPONSE ELEMENT BINDING PROTEIN-TRIGGERED TRANSCRIPTIONAL ACTIVATION OF DNMT1 GENE. BLOCKING THIS UPREGULATION PREVENTED NERVE INJURY-INDUCED DNA METHYLATION WITHIN THE PROMOTER AND 5'-UNTRANSLATED REGION OF KCNA2 GENE, RESCUED KCNA2 EXPRESSION AND TOTAL KV CURRENT, ATTENUATED HYPEREXCITABILITY IN THE INJURED DRG NEURONS, AND ALLEVIATED NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES. GIVEN THAT KCNA2 IS A KEY PLAYER IN NEUROPATHIC PAIN, OUR FINDINGS SUGGEST THAT DRG DNMT1 MAY BE A POTENTIAL TARGET FOR NEUROPATHIC PAIN MANAGEMENT.SIGNIFICANCE STATEMENT IN THE PRESENT STUDY, WE REPORTED THAT DNMT1, A CANONICAL DNA MAINTENANCE METHYLTRANSFERASE, IS UPREGULATED VIA THE ACTIVATION OF THE TRANSCRIPTION FACTOR CREB IN THE INJURED DRG AFTER PERIPHERAL NERVE INJURY. THIS UPREGULATION WAS RESPONSIBLE FOR NERVE INJURY-INDUCED DE NOVO DNA METHYLATION WITHIN THE PROMOTER AND 5'-UNTRANSLATED REGION OF THE KCNA2 GENE, REDUCTIONS IN KCNA2 EXPRESSION AND KV CURRENT AND INCREASES IN NEURONAL EXCITABILITY IN THE INJURED DRG. SINCE PHARMACOLOGICAL INHIBITION OR GENETIC KNOCKDOWN OF DRG DNMT1 ALLEVIATED NERVE INJURY-INDUCED PAIN HYPERSENSITIVITIES, DRG DNMT1 CONTRIBUTES TO NEUROPATHIC PAIN GENESIS PARTIALLY THROUGH REPRESSION OF DRG KCNA2 GENE EXPRESSION. 2019 6 2885 23 G9A PARTICIPATES IN NERVE INJURY-INDUCED KCNA2 DOWNREGULATION IN PRIMARY SENSORY NEURONS. NERVE INJURY-INDUCED DOWNREGULATION OF VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT KCNA2 IN THE DORSAL ROOT GANGLION (DRG) IS CRITICAL FOR DRG NEURONAL EXCITABILITY AND NEUROPATHIC PAIN GENESIS. HOWEVER, HOW NERVE INJURY CAUSES THIS DOWNREGULATION IS STILL ELUSIVE. EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE 2, ALSO KNOWN AS G9A, METHYLATES HISTONE H3 ON LYSINE RESIDUE 9 TO PREDOMINANTLY PRODUCE A DYNAMIC HISTONE DIMETHYLATION, RESULTING IN CONDENSED CHROMATIN AND GENE TRANSCRIPTIONAL REPRESSION. WE SHOWED HERE THAT BLOCKING NERVE INJURY-INDUCED INCREASE IN G9A RESCUED KCNA2 MRNA AND PROTEIN EXPRESSION IN THE AXOTOMIZED DRG AND ATTENUATED THE DEVELOPMENT OF NERVE INJURY-INDUCED PAIN HYPERSENSITIVITY. MIMICKING THIS INCREASE DECREASED KCNA2 MRNA AND PROTEIN EXPRESSION, REDUCED KV CURRENT, AND INCREASED EXCITABILITY IN THE DRG NEURONS AND LED TO SPINAL CORD CENTRAL SENSITIZATION AND NEUROPATHIC PAIN-LIKE SYMPTOMS. G9A MRNA IS CO-LOCALIZED WITH KCNA2 MRNA IN THE DRG NEURONS. THESE FINDINGS INDICATE THAT G9A CONTRIBUTES TO NEUROPATHIC PAIN DEVELOPMENT THROUGH EPIGENETIC SILENCING OF KCNA2 IN THE AXOTOMIZED DRG. 2016 7 4545 30 MUTANT P53 GAIN OF FUNCTION AND CHEMORESISTANCE: THE ROLE OF MUTANT P53 IN RESPONSE TO CLINICAL CHEMOTHERAPY. PURPOSE: TO REVIEW MECHANISMS UNDERLYING MUTANT P53 (MUTP53) GAIN OF FUNCTION (GOF) AND MUTP53-INDUCED CHEMORESISTANCE, AND TO INVESTIGATE THE ROLE OF MUTP53 IN RESPONSE TO CLINICAL CHEMOTHERAPY. METHODS: WE SEARCHED THE PUBMED DATABASE FOR CLINICAL STUDIES FROM THE PAST DECADE, INCLUDING DATA EVALUATING THE IMPACT OF MUTP53 IN CLINICAL CHEMOTHERAPY RESPONSE. RESULTS: INTERACTIONS BETWEEN MUTP53 AND TRANSCRIPTIONAL FACTORS, PROTEINS OR DNA STRUCTURES, AS WELL AS EPIGENETIC REGULATION, CONTRIBUTE TO MUTP53 GOF. MAJOR MECHANISMS OF MUTP53-INDUCED CHEMORESISTANCE INCLUDE ENHANCED DRUG EFFLUX AND METABOLISM, PROMOTING SURVIVAL, INHIBITING APOPTOSIS, UPREGULATING DNA REPAIR, SUPPRESSING AUTOPHAGY, ELEVATING MICROENVIRONMENTAL RESISTANCE AND INDUCING A STEM-LIKE PHENOTYPE. CLINICALLY, MUTP53 PREDICTED RESISTANCE TO CHEMOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA, AND ESOPHAGEAL AND OROPHARYNGEAL CANCERS, BUT ITS IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA WAS UNCLEAR. IN BLADDER CANCER, MUTP53 DID NOT PREDICT RESISTANCE, WHEREAS IN SOME BREAST AND OVARIAN CANCERS, IT WAS ASSOCIATED WITH SENSITIVITY TO CERTAIN CHEMOTHERAPEUTIC AGENTS. CONCLUSION: MUTP53 HAS AN INTRICATE ROLE IN THE RESPONSE TO CLINICAL CHEMOTHERAPY AND SHOULD NOT BE INTERPRETED IN ISOLATION. FURTHERMORE, WHEN PREDICTING TUMOR RESPONSE TO CHEMOTHERAPY BASED ON THE P53 STATUS, THE DRUGS USED SHOULD ALSO BE TAKEN INTO CONSIDERATION. THESE CONCEPTS REQUIRE FURTHER INVESTIGATION. 2017 8 3175 33 H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA CELLS INDUCED BY IMATINIB. INCREASING EVIDENCE SUGGESTS THAT HISTONE H2AX PLAYS A CRITICAL ROLE IN REGULATION OF TUMOR CELL APOPTOSIS AND ACTS AS A NOVEL HUMAN TUMOR SUPPRESSOR PROTEIN. HOWEVER, THE ACTION OF H2AX IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS IS UNKNOWN. THE DETAILED MECHANISM AND EPIGENETIC REGULATION BY H2AX REMAIN ELUSIVE IN CANCER CELLS. HERE, WE REPORT THAT H2AX WAS INVOLVED IN APOPTOSIS OF CML CELLS. OVEREXPRESSION OF H2AX INCREASED APOPTOTIC SENSITIVITY OF CML CELLS (K562) INDUCED BY IMATINIB. HOWEVER, OVEREXPRESSION OF SER139-MUTATED H2AX (BLOCKING PHOSPHORYLATION) DECREASED SENSITIVITY OF K562 CELLS TO APOPTOSIS. SIMILARLY, KNOCKDOWN OF H2AX MADE K562 CELLS RESISTANT TO APOPTOTIC INDUCTION. THESE RESULTS REVEALED THAT THE FUNCTION OF H2AX INVOLVED IN APOPTOSIS IS STRICTLY RELATED TO ITS PHOSPHORYLATION (SER139). OUR DATA FURTHER INDICATED THAT IMATINIB MAY STIMULATE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) FAMILY MEMBER P38, AND H2AX PHOSPHORYLATION FOLLOWED A SIMILAR TIME COURSE, SUGGESTING A PARALLEL RESPONSE. H2AX PHOSPHORYLATION CAN BE BLOCKED BY P38 SIRNA OR ITS INHIBITOR. THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION WAS REGULATED BY P38 MAPK PATHWAY IN K562 CELLS. HOWEVER, THE P38 MAPK DOWNSTREAM, MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE-1 AND -2, WHICH PHOSPHORYLATED HISTONE H3, WERE NOT REQUIRED FOR H2AX PHOSPHORYLATION DURING APOPTOSIS. FINALLY, WE PROVIDED EPIGENETIC EVIDENCE THAT H2AX PHOSPHORYLATION REGULATED APOPTOSIS-RELATED GENE BIM EXPRESSION. BLOCKING OF H2AX PHOSPHORYLATION INHIBITED BIM GENE EXPRESSION. TAKEN TOGETHER, THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CML CELLS INDUCED BY IMATINIB. 2014 9 3204 42 HDAC3 REGULATES GINGIVAL FIBROBLAST INFLAMMATORY RESPONSES IN PERIODONTITIS. HISTONE DEACETYLASES (HDACS) ARE IMPORTANT REGULATORS OF GENE EXPRESSION THAT ARE ABERRANTLY REGULATED IN SEVERAL INFLAMMATORY AND INFECTIOUS DISEASES. HDAC INHIBITORS (HDACI) SUPPRESS INFLAMMATORY ACTIVATION OF VARIOUS CELL TYPES THROUGH EPIGENETIC AND NON-EPIGENETIC MECHANISMS, AND AMELIORATE PATHOLOGY IN A MOUSE MODEL OF PERIODONTITIS. ACTIVATION OF GINGIVAL FIBROBLASTS (GFS) SIGNIFICANTLY CONTRIBUTES TO THE DEVELOPMENT OF PERIODONTITIS AND THE ANAEROBIC BACTERIUM PORPHYROMONAS GINGIVALIS PLAYS A KEY ROLE IN DRIVING CHRONIC INFLAMMATION. HERE, WE ANALYZED THE ROLE OF HDACS IN INFLAMMATORY RESPONSES OF GFS. PAN-HDACI SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) AND/OR ITF2357 (GIVINOSTAT) SIGNIFICANTLY REDUCED TNFALPHA- AND P. GINGIVALIS-INDUCIBLE EXPRESSION AND/OR PRODUCTION OF A CLUSTER OF INFLAMMATORY MEDIATORS IN HEALTHY DONOR GFS (IL1B, CCL2, CCL5, CXCL10, COX2, AND MMP3) WITHOUT AFFECTING CELL VIABILITY. SELECTIVE INHIBITION OF HDAC3/6, BUT NOT SPECIFIC HDAC1, HDAC6, OR HDAC8 INHIBITION, REPRODUCED THE SUPPRESSIVE EFFECTS OF PAN-HDACI ON THE INFLAMMATORY GENE EXPRESSION PROFILE INDUCED BY TNFALPHA AND P. GINGIVALIS, SUGGESTING A CRITICAL ROLE FOR HDAC3 IN GF INFLAMMATORY ACTIVATION. CONSISTENTLY, SILENCING OF HDAC3 EXPRESSION WITH SIRNA LARGELY RECAPITULATED THE EFFECTS OF HDAC3/6I ON MRNA LEVELS OF INFLAMMATORY MEDIATORS IN P. GINGIVALIS-INFECTED GFS. IN CONTRAST, P. GINGIVALIS INTERNALIZATION AND INTRACELLULAR SURVIVAL IN GFS REMAINED UNAFFECTED BY HDACI. ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASES AND NFKAPPAB SIGNALING WAS UNAFFECTED BY GLOBAL OR HDAC3/6-SELECTIVE HDACI, AND NEW PROTEIN SYNTHESIS WAS NOT REQUIRED FOR GENE SUPPRESSION BY HDACI. FINALLY, PAN-HDACI AND HDAC3/6I SUPPRESSED P. GINGIVALIS-INDUCED EXPRESSION OF IL1B, CCL2, CCL5, CXCL10, MMP1, AND MMP3 IN GFS FROM PATIENTS WITH PERIODONTITIS. OUR RESULTS IDENTIFY HDAC3 AS AN IMPORTANT REGULATOR OF INFLAMMATORY GENE EXPRESSION IN GFS AND SUGGEST THAT THERAPEUTIC TARGETING OF HDAC ACTIVITY, IN PARTICULAR HDAC3, MAY BE CLINICALLY BENEFICIAL IN SUPPRESSING INFLAMMATION IN PERIODONTAL DISEASE. 2020 10 6172 37 THE HDAC1/C-JUN COMPLEX IS ESSENTIAL IN THE PROMOTION OF NERVE INJURY-INDUCED NEUROPATHIC PAIN THROUGH JNK SIGNALING. HISTONE DEACETYLASE INHIBITORS (HDACIS) INTERFERE WITH THE EPIGENETIC PROCESS OF HISTONE ACETYLATION AND ARE KNOWN TO HAVE ANALGESIC PROPERTIES IN MODELS OF CHRONIC INFLAMMATORY PAIN. ADMINISTRATION OF A SELECTIVE HDAC1 INHIBITOR (LG325) IN SNI-SUBJECTED MICE SIGNIFICANTLY ATTENUATED BEHAVIOR RELATED TO INJURY-INDUCED PAIN. UNDERSTANDING THE HDAC1 PATHWAY IN EPIGENETIC REGULATION OF PATHOLOGICAL PAIN IS OF GREAT MEDICAL RELEVANCE. SPARED NERVE INJURY (SNI) MICE SHOWED A SIGNIFICANT INCREASE IN THE HDAC1 PROTEIN LEVELS WITHIN SPINAL CORD IN COINCIDENCE WITH THE NOCICEPTIVE PHENOTYPE AT 1 AND 3 WEEKS AFTER NERVE INJURY. NO VARIATION IN HDAC3, DNMT3A, ACH3, MBD3 AND MECP2 LEVELS WAS DETECTED. INCREASED EXPRESSION OF HDAC1 IS ACCOMPANIED BY ACTIVATION OF THE JNK-C-JUN SIGNALING PATHWAY. A ROBUST SPINAL JNK-1 OVERPHOSPHORYLATION WAS OBSERVED POST NERVE-INJURY ALONG WITH A SELECTIVE JNK-DEPENDENT INCREASE IN P-C-JUN AND HDAC1 PROTEIN LEVELS. CO-IMMUNOPRECIPITATION EXPERIMENTS SHOWED THE PRESENCE OF A HETERODIMERIC COMPLEX BETWEEN HDAC1 AND C-JUN IN SNI MICE INDICATING THAT THESE TRANSCRIPTION FACTORS CAN ACT TOGETHER TO REGULATE TRANSCRIPTION THROUGH HETERODIMERIZATION. STIMULATION OF C-JUN PHOSPHORYLATION WAS PREVENTED BY THE SELECTIVE HDAC1 INHIBITOR LG325. WE FOUND THAT HDAC1 WAS ASSOCIATED WITH C-JUN IN NUCLEI OF SPINAL DORSAL HORN ASTROCYTES EXPRESSING JNK. ON THE OTHER HAND, THE PRESENCE OF HDAC1 AND C-JUN INTERACTION WAS NOT DETECTED IN CONTROL MICE. THESE FINDINGS PROVIDE NEW INSIGHTS INTO THE MECHANISMS UNDERLYING THE ANTI-NOCICEPTIVE ACTIVITY OF HDAC INHIBITORS. TAKEN TOGETHER, THESE DATA SUPPORT A ROLE FOR HISTONE DEACETYLASE IN THE EMERGENCE OF NEUROPATHIC PAIN. 2018 11 5574 30 ROLE OF MICRORNA-143 IN NERVE INJURY-INDUCED UPREGULATION OF DNMT3A EXPRESSION IN PRIMARY SENSORY NEURONS. PERIPHERAL NERVE INJURY INCREASED THE EXPRESSION OF THE DNA METHYLTRANSFERASE 3A (DNMT3A) MRNA AND ITS ENCODING DNMT3A PROTEIN IN INJURED DORSAL ROOT GANGLIA (DRG). THIS INCREASE IS CONSIDERED AS AN ENDOGENOUS INSTIGATOR IN NEUROPATHIC PAIN GENESIS THROUGH EPIGENETIC SILENCING OF PAIN-ASSOCIATED GENES (SUCH AS OPRM1) IN INJURED DRG. HOWEVER, HOW DRG DNMT3A IS INCREASED FOLLOWING PERIPHERAL NERVE INJURY IS STILL ELUSIVE. WE REPORTED HERE THAT PERIPHERAL NERVE INJURY CAUSED BY THE FIFTH SPINAL NERVE LIGATION (SNL) DOWNREGULATED MICRORNA (MIR)-143 EXPRESSION IN INJURED DRG. THIS DOWNREGULATION WAS REQUIRED FOR SNL-INDUCED DRG DNMT3A INCREASE AS RESCUING MIR-143 DOWNREGULATION THROUGH MICROINJECTION OF MIR-143 MIMICS INTO INJURED DRG BLOCKED THE SNL-INDUCED INCREASE IN DNMT3A AND RESTORED THE SNL-INDUCED DECREASES IN OPRM1 MRNA AND ITS ENCODING MU OPIOID RECEPTOR (MOR) IN INJURED DRG, IMPAIRED SPINAL CORD CENTRAL SENSITIZATION AND NEUROPATHIC PAIN, AND IMPROVED MORPHINE ANALGESIC EFFECTS FOLLOWING SNL. MIMICKING SNL-INDUCED DRG MIR-143 DOWNREGULATION THROUGH DRG MICROINJECTION OF MIR143 INHIBITORS IN NAIVE RATS INCREASED THE EXPRESSION OF DNMT3A AND REDUCED THE EXPRESSION OF OPRM1 MRNA AND MOR IN INJECTED DRG AND PRODUCED NEUROPATHIC PAIN-LIKE SYMPTOMS. THESE FINDINGS SUGGEST THAT MIR-143 IS A NEGATIVE REGULATOR IN DNMT3A EXPRESSION IN THE DRG UNDER NEUROPATHIC PAIN CONDITIONS AND MAY BE A POTENTIAL TARGET FOR THERAPEUTIC MANAGEMENT OF NEUROPATHIC PAIN. 2017 12 5459 31 RESEARCH ON THE EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA. PTPN6, A TYROSINE PHOSPHATASE PROTEIN, PLAYS A NEGATIVE ROLE IN CELL SIGNAL TRANSDUCTION AND IS NEGATIVELY CORRELATED WITH TUMOUR FORMATION AND GROWTH. HOWEVER, EPIGENETIC REGULATION MECHANISM OF THE PTPN6 GENE IN ADVANCED CHRONIC MYELOID LEUKAEMIA (CML) REMAINS UNCLEAR. THIS STUDY INVESTIGATED BONE MARROW OR BLOOD SAMPLES FROM 44 CML PATIENTS AND 10 HEALTHY VOLUNTEERS. KCL22 AND K562 CELLS WERE CULTURED AND TREATED WITH DEMETHYLATION DRUGS AND HISTONE DEACETYLASE INHIBITORS. REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC PCR, BISULFITE SEQUENCING PCR, WESTERN BLOTTING, CO-IMMUNOPRECIPITATION AND CHROMATIN IMMUNOPRECIPITATION (CHIP) WAS PERFORMED. PTPN6 WAS DOWN-REGULATED IN CELL LINES AND PATIENTS WITH ADVANCED PHASE CML, WHEREAS DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1 WERE UP-REGULATED. TREATMENT WITH 5-AZACYTIDINE, DECITABINE, SODIUM VALPROATE AND LBH589 INCREASED PTPN6 EXPRESSION, BUT DECREASED THAT OF DNMT1, DNMT3A, MECP2, MBD2 AND HDAC1. IMMUNOPRECIPITATION AND MASS SPECTROMETRY SHOWED THAT HDAC1 COMBINED DIRECTLY WITH PTPN6. CHIP-SEQ SHOWED THAT HDAC1 DID NOT COMBINE WITH THE PROMOTER REGION OF PTPN6, WHILE MAPK, AKT, STAT5, JAK2 AND MYC PROMOTER REGIONS ALL COMBINED WITH HDAC1. PTPN6 IS ASSOCIATED WITH PROGRESSION OF CML. LOW EXPRESSION LEVEL OF PTPN6 WAS ASSOCIATED WITH DNA METHYLATION AND REGULATED BY HISTONE ACETYLATION. HDAC1 PARTICIPATES IN THE REGULATION OF PTPN6. 2017 13 5266 35 PROMOTED INTERACTION OF C/EBPALPHA WITH DEMETHYLATED CXCR3 GENE PROMOTER CONTRIBUTES TO NEUROPATHIC PAIN IN MICE. DNA METHYLATION HAS BEEN IMPLICATED IN THE PATHOGENESIS OF CHRONIC PAIN. HOWEVER, THE SPECIFIC GENES REGULATED BY DNA METHYLATION UNDER NEUROPATHIC PAIN CONDITION REMAIN LARGELY UNKNOWN. HERE WE INVESTIGATED HOW CHEMOKINE RECEPTOR CXCR3 IS REGULATED BY DNA METHYLATION AND HOW IT CONTRIBUTES TO NEUROPATHIC PAIN INDUCED BY SPINAL NERVE LIGATION (SNL) IN MICE. SNL INCREASED CXCR3 MRNA AND PROTEIN EXPRESSION IN THE NEURONS OF THE SPINAL CORD. MEANWHILE, THE CPG (5'-CYTOSINE-PHOSPHATE-GUANINE-3') ISLAND IN THE CXCR3 GENE PROMOTER REGION WAS DEMETHYLATED, AND THE EXPRESSION OF DNA METHYLTRANSFERASE 3B (DNMT3B) WAS DECREASED. SNL ALSO INCREASED THE BINDING OF CCAAT (CYTIDINE-CYTIDINE-ADENOSINE-ADENOSINE-THYMIDINE)/ENHANCER BINDING PROTEIN ALPHA (C/EBPALPHA) WITH CXCR3 PROMOTER AND DECREASED THE BINDING OF DNMT3B WITH CXCR3 PROMOTER IN THE SPINAL CORD. C/EBPALPHA EXPRESSION WAS INCREASED IN SPINAL NEURONS AFTER SNL, AND INHIBITION OF C/EBPALPHA BY INTRATHECAL SMALL INTERFERING RNA ATTENUATED SNL-INDUCED PAIN HYPERSENSITIVITY AND REDUCED CXCR3 EXPRESSION. FURTHERMORE, SNL-INDUCED MECHANICAL ALLODYNIA AND HEAT HYPERALGESIA WERE MARKEDLY REDUCED IN CXCR3(-/-) MICE. SPINAL INHIBITION OF CXCR3 BY SHRNA OR CXCR3 ANTAGONIST ALSO ATTENUATED ESTABLISHED NEUROPATHIC PAIN. MOREOVER, CXCL10, THE LIGAND OF CXCR3, WAS INCREASED IN SPINAL NEURONS AND ASTROCYTES AFTER SNL. SUPERFUSING SPINAL CORD SLICES WITH CXCL10 ENHANCED SPONTANEOUS EPSCS AND POTENTIATED NMDA-INDUCED AND AMPA-INDUCED CURRENTS OF LAMINA II NEURONS. FINALLY, INTRATHECAL INJECTION OF CXCL10 INDUCED CXCR3-DEPENDENT PAIN HYPERSENSITIVITY IN NAIVE MICE. COLLECTIVELY, OUR RESULTS DEMONSTRATED THAT CXCR3, INCREASED BY DNA DEMETHYLATION AND THE ENHANCED INTERACTION WITH C/EBPALPHA, CAN BE ACTIVATED BY CXCL10 TO FACILITATE EXCITATORY SYNAPTIC TRANSMISSION AND CONTRIBUTE TO THE MAINTENANCE OF NEUROPATHIC PAIN. SIGNIFICANCE STATEMENT: PERIPHERAL NERVE INJURY INDUCES CHANGES OF GENE EXPRESSION IN THE SPINAL CORD THAT MAY CONTRIBUTE TO THE PATHOGENESIS OF NEUROPATHIC PAIN. CXCR3 IS A CHEMOKINE RECEPTOR. WHETHER IT IS INVOLVED IN NEUROPATHIC PAIN AND HOW IT IS REGULATED AFTER NERVE INJURY REMAIN LARGELY UNKNOWN. OUR STUDY DEMONSTRATES THAT SPINAL NERVE LIGATION DOWNREGULATES THE EXPRESSION OF DNMT3B, WHICH MAY CAUSE DEMETHYLATION OF CXCR3 GENE PROMOTER AND FACILITATE THE BINDING OF CCAAT/ENHANCER BINDING PROTEIN ALPHA WITH CXCR3 PROMOTER AND FURTHER INCREASE CXCR3 EXPRESSION IN SPINAL NEURONS. THE UPREGULATED CXCR3 MAY CONTRIBUTE TO NEUROPATHIC PAIN BY FACILITATING CENTRAL SENSITIZATION. OUR STUDY REVEALS AN EPIGENETIC MECHANISM UNDERLYING CXCR3 EXPRESSION AND ALSO SUGGESTS THAT TARGETING THE EXPRESSION OR ACTIVATION OF CXCR3 SIGNALING MAY OFFER NEW THERAPEUTICS FOR NEUROPATHIC PAIN. 2017 14 4160 32 MECP2 EPIGENETIC SILENCING OF OPRM1 GENE IN PRIMARY SENSORY NEURONS UNDER NEUROPATHIC PAIN CONDITIONS. OPIOIDS ARE THE LAST OPTION FOR THE PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN, BUT THEIR ANTINOCICEPTIVE EFFECTS ARE LIMITED. DECREASED MU OPIOID RECEPTOR (MOR) EXPRESSION IN THE PERIPHERAL NERVOUS SYSTEM MAY CONTRIBUTE TO THIS. HERE, WE SHOWED THAT NERVE INJURY INDUCED HYPERMETHYLATION OF THE OPRM1 GENE PROMOTER AND AN INCREASED EXPRESSION OF METHYL-CPG BINDING PROTEIN 2 (MECP2) IN INJURED DORSAL ROOT GANGLION (DRG). THE DOWNREGULATION OF MOR IN THE DRG IS CLOSELY RELATED TO THE AUGMENTATION OF MECP2, AN EPIGENETIC REPRESSOR, WHICH COULD RECRUIT HDAC1 AND BIND TO THE METHYLATED REGIONS OF THE OPRM1 GENE PROMOTER. MECP2 KNOCKDOWN RESTORED THE EXPRESSION OF MOR IN INJURED DRG AND ENHANCED THE ANALGESIC EFFECT OF MORPHINE, WHILE THE MIMICKING OF THIS INCREASE VIA THE INTRATHECAL INFUSION OF VIRAL VECTOR-MEDIATED MECP2 WAS SUFFICIENT TO REDUCE MOR IN THE DRG. MOREOVER, HDAC1 INHIBITION WITH SUBEROYLANILIDE HYDROXAMIC ACID, AN HDAC INHIBITOR, ALSO PREVENTED MOR REDUCTION IN THE DRG OF NEUROPATHIC PAIN MICE, CONTRIBUTING TO THE AUGMENTATION OF MORPHINE ANALGESIA EFFECTS. MECHANISTICALLY, UPREGULATED MECP2 PROMOTES THE BINDING OF A HIGH LEVEL OF HDCA1 TO HYPERMETHYLATED REGIONS OF THE OPRM1 GENE PROMOTER, REDUCES THE ACETYLATION OF HISTONE H3 (ACH3) LEVELS OF THE OPRM1 GENE PROMOTER, AND ATTENUATES OPRM1 TRANSCRIPTION IN INJURED DRG. THUS, UPREGULATED MECP2 AND HDAC1 IN OPRM1 GENE PROMOTER SITES, NEGATIVELY REGULATES MOR EXPRESSION IN INJURED DRG, MITIGATING THE ANALGESIC EFFECT OF THE OPIOIDS. TARGETING MECP2/HDAC1 MAY THUS PROVIDE A NEW SOLUTION FOR IMPROVING THE THERAPEUTIC EFFECT OF OPIOIDS IN A CLINICAL SETTING. 2021 15 2326 28 EPIGENETIC REGULATION OF HOTAIR IN ADVANCED CHRONIC MYELOID LEUKEMIA. PURPOSE: CHRONIC MYELOID LEUKEMIA (CML) ACCOUNTS FOR ~10% OF LEUKEMIA CASES, AND ITS PROGRESSION INVOLVES EPIGENETIC GENE REGULATION. THIS STUDY INVESTIGATED EPIGENETIC REGULATION OF HOTAIR AND ITS TARGET MICRORNA, MIR-143, IN ADVANCED CML. PATIENTS AND METHODS: WE FIRST ISOLATED BONE MARROW MONONUCLEAR CELLS FROM 70 PATIENTS WITH DIFFERENT PHASES OF CML AND FROM HEALTHY DONORS AS NORMAL CONTROL; WE ALSO CULTURED K562 AND KCL22 CELLS, TREATED WITH DEMETHYLATION DRUG; MTT ASSAY, FLOW CYTOMETRY, QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QPCR), METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP), WESTERN BLOT, LUCIFERASE ASSAY, RNA PULL-DOWN ASSAY AND RNA-BINDING PROTEIN IMMUNOPRECIPITATION (RIP) ASSAY WERE PERFORMED. RESULT: AS MEASURED BY QPCR, HOTAIR EXPRESSION IN K562 CELLS, KCL22 CELLS, AND SAMPLES FROM CASES OF ADVANCED-STAGE CML INCREASED WITH LEVELS OF SEVERAL DNA METHYLTRANSFERASES AND HISTONE DEACETYLATES, INCLUDING DNMT1, DNMT3A, HDAC1, EZH2, AND LSD1, AND MIR-143 LEVELS WERE DECREASED AND HOTAIR LEVELS WERE INCREASED. TREATMENT WITH 5-AZACYTIDINE, A DNA METHYLATION INHIBITOR, DECREASED DNMT1, DNMT3A, HDAC1, EZH2, LSD1 MRNA, PROTEIN LEVELS, AND HOTAIR MRNA LEVELS BUT INCREASED MIR-143 LEVELS. HOTAIR KNOCKDOWN AND MIR-143 OVEREXPRESSION BOTH INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS IN KCL22 AND K562 CELLS THROUGH THE PI3K/AKT PATHWAY. RNA PULL-DOWN, MASS SPECTROMETRY, AND RIP ASSAYS SHOWED THAT HOTAIR INTERACTED WITH EZH2 AND LSD1. A DUAL-LUCIFERASE ASSAY DEMONSTRATED THAT HOTAIR INTERACTED WITH MIR-143. CONCLUSION: OUR FINDINGS DEMONSTRATE THE KEY EPIGENETIC INTERACTIONS OF HOTAIR RELATED TO CML PROGRESSION AND SUGGEST HOTAIR AS A POTENTIAL THERAPEUTIC TARGET FOR ADVANCED CML. FURTHERMORE, OUR RESULTS SUPPORT THE USE OF DEMETHYLATION DRUGS AS A CML TREATMENT STRATEGY. 2018 16 2884 32 G9A IS ESSENTIAL FOR EPIGENETIC SILENCING OF K(+) CHANNEL GENES IN ACUTE-TO-CHRONIC PAIN TRANSITION. NEUROPATHIC PAIN IS A DEBILITATING CLINICAL PROBLEM AND DIFFICULT TO TREAT. NERVE INJURY CAUSES A LONG-LASTING REDUCTION IN K(+) CHANNEL EXPRESSION IN THE DORSAL ROOT GANGLION (DRG), BUT LITTLE IS KNOWN ABOUT THE EPIGENETIC MECHANISMS INVOLVED. WE FOUND THAT NERVE INJURY INCREASED DIMETHYLATION OF LYS9 ON HISTONE H3 (H3K9ME2) AT KCNA4, KCND2, KCNQ2 AND KCNMA1 PROMOTERS BUT DID NOT AFFECT LEVELS OF DNA METHYLATION ON THESE GENES IN DRGS. NERVE INJURY INCREASED ACTIVITY OF EUCHROMATIC HISTONE-LYSINE N-METHYLTRANSFERASE-2 (G9A), HISTONE DEACETYLASES AND ENHANCER OF ZESTE HOMOLOG-2 (EZH2), BUT ONLY G9A INHIBITION CONSISTENTLY RESTORED K(+) CHANNEL EXPRESSION. SELECTIVE KNOCKOUT OF THE GENE ENCODING G9A IN DRG NEURONS COMPLETELY BLOCKED K(+) CHANNEL SILENCING AND CHRONIC PAIN DEVELOPMENT AFTER NERVE INJURY. REMARKABLY, RNA SEQUENCING ANALYSIS REVEALED THAT G9A INHIBITION NOT ONLY REACTIVATED 40 OF 42 SILENCED GENES ASSOCIATED WITH K(+) CHANNELS BUT ALSO NORMALIZED 638 GENES DOWN- OR UPREGULATED BY NERVE INJURY. THUS G9A HAS A DOMINANT FUNCTION IN TRANSCRIPTIONAL REPRESSION OF K(+) CHANNELS AND IN ACUTE-TO-CHRONIC PAIN TRANSITION AFTER NERVE INJURY. 2015 17 131 23 A2B ADENOSINE SIGNALING REPRESSES CIITA TRANSCRIPTION VIA AN EPIGENETIC MECHANISM IN VASCULAR SMOOTH MUSCLE CELLS. CHRONIC INFLAMMATION PLAYS A MAJOR ROLE IN THE PATHOGENESIS OF ATHEROSCLEROSIS. VASCULAR SMOOTH MUSCLE CELLS (VSMC), BY EXPRESSING AND PRESENTING MAJOR HISTOCOMPATIBILITY COMPLEX II (MHC II) MOLECULES, HELP RECRUIT T LYMPHOCYTE AND INITIATE THE INFLAMMATORY RESPONSE WITHIN THE VASCULATURE. WE HAVE PREVIOUSLY SHOWN THAT VSMCS ISOLATED FROM MICE WITH DEFICIENT ADENOSINE A2B RECEPTOR (A2B-NULL) EXHIBIT HIGHER EXPRESSION OF CLASS II TRANSACTIVATOR (CIITA), THE MASTER REGULATOR OF MHC II TRANSCRIPTION, COMPARED TO WILD TYPE LITTERMATES. HERE WE REPORT THAT ACTIVATION OF A2B ADENOSINE SIGNALING SUPPRESSES CIITA EXPRESSION IN HUMAN AORTIC SMOOTH MUSCLE CELLS. DOWN-REGULATION OF CIITA EXPRESSION WAS LARGELY ATTRIBUTABLE TO TRANSCRIPTIONAL REPRESSION OF TYPE III AND IV PROMOTERS. CHROMATIN IMMUNOPRECIPITATION (CHIP) ANALYSES REVEALED THAT A2B SIGNALING REPRESSED CIITA TRANSCRIPTION BY ATTENUATING SPECIFIC HISTONE MODIFICATIONS ON THE CIITA PROMOTERS IN A STAT1-DEPENDENT MANNER. STAT1 INTERACTED WITH PCAF/GCN5, HISTONE H3K9 ACETYLTRANSFERASES, AND WDR5, A KEY COMPONENT OF THE MAMMALIAN H3K4 METHYLTRANSFERASE COMPLEX, TO ACTIVATE CIITA TRANSCRIPTION. A2B SIGNALING PREVENTED RECRUITMENT OF PCAF/GCN5 AND WDR5 TO THE CIITA PROMOTERS IN A STAT1-DEPENDENT MANNER. IN CONCLUSION, OUR DATA SUGGEST THAT ADENOSINE A2B SIGNALING REPRESSES CIITA TRANSCRIPTION IN VSMCS BY MANIPULATING THE INTERACTION BETWEEN STAT1 AND THE EPIGENETIC MACHINERY. 2015 18 4615 29 NERVE INJURY DIMINISHES OPIOID ANALGESIA THROUGH LYSINE METHYLTRANSFERASE-MEDIATED TRANSCRIPTIONAL REPRESSION OF MU-OPIOID RECEPTORS IN PRIMARY SENSORY NEURONS. THE MU-OPIOID RECEPTOR (MOR, ENCODED BY OPRM1) AGONISTS ARE THE MAINSTAY ANALGESICS FOR TREATING MODERATE TO SEVERE PAIN. NERVE INJURY CAUSES DOWN-REGULATION OF MORS IN THE DORSAL ROOT GANGLION (DRG) AND DIMINISHES THE OPIOID EFFECT ON NEUROPATHIC PAIN. HOWEVER, THE EPIGENETIC MECHANISMS UNDERLYING THE DIMINISHED MOR EXPRESSION CAUSED BY NERVE INJURY ARE NOT CLEAR. G9A (ENCODED BY EHMT2), A HISTONE 3 AT LYSINE 9 METHYLTRANSFERASE, IS A KEY CHROMATIN REGULATOR RESPONSIBLE FOR GENE SILENCING. IN THIS STUDY, WE DETERMINED THE ROLE OF G9A IN DIMINISHED MOR EXPRESSION AND OPIOID ANALGESIC EFFECTS IN ANIMAL MODELS OF NEUROPATHIC PAIN. WE FOUND THAT NERVE INJURY IN RATS INDUCED A LONG-LASTING REDUCTION IN THE EXPRESSION LEVEL OF MORS IN THE DRG BUT NOT IN THE SPINAL CORD. NERVE INJURY CONSISTENTLY INCREASED THE ENRICHMENT OF THE G9A PRODUCT HISTONE 3 AT LYSINE 9 DIMETHYLATION IN THE PROMOTER OF OPRM1 IN THE DRG. G9A INHIBITION OR SIRNA KNOCKDOWN FULLY REVERSED MOR EXPRESSION IN THE INJURED DRG AND POTENTIATED THE MORPHINE EFFECT ON PAIN HYPERSENSITIVITY INDUCED BY NERVE INJURY. IN MICE LACKING EHMT2 IN DRG NEURONS, NERVE INJURY FAILED TO REDUCE THE EXPRESSION LEVEL OF MORS AND THE MORPHINE EFFECT. IN ADDITION, G9A INHIBITION OR EHMT2 KNOCKOUT IN DRG NEURONS NORMALIZED NERVE INJURY-INDUCED REDUCTION IN THE INHIBITORY EFFECT OF THE OPIOID ON SYNAPTIC GLUTAMATE RELEASE FROM PRIMARY AFFERENT NERVES. OUR FINDINGS INDICATE THAT G9A CONTRIBUTES CRITICALLY TO TRANSCRIPTIONAL REPRESSION OF MORS IN PRIMARY SENSORY NEURONS IN NEUROPATHIC PAIN. G9A INHIBITORS MAY BE USED TO ENHANCE THE OPIOID ANALGESIC EFFECT IN THE TREATMENT OF CHRONIC NEUROPATHIC PAIN. 2016 19 4618 26 NERVE INJURY-INDUCED EPIGENETIC SILENCING OF OPIOID RECEPTORS CONTROLLED BY DNMT3A IN PRIMARY AFFERENT NEURONS. OPIOIDS ARE THE GOLD STANDARD FOR PHARMACOLOGICAL TREATMENT OF NEUROPATHIC PAIN, BUT THEIR ANALGESIC EFFECTS ARE UNSATISFACTORY IN PART DUE TO NERVE INJURY-INDUCED DOWNREGULATION OF OPIOID RECEPTORS IN DORSAL ROOT GANGLIA (DRG) NEURONS. HOW NERVE INJURY DRIVES SUCH DOWNREGULATION REMAINS ELUSIVE. DNA METHYLTRANSFERASE (DNMT)-TRIGGERED DNA METHYLATION REPRESSES GENE EXPRESSION. WE SHOW HERE THAT BLOCKING THE NERVE INJURY-INDUCED INCREASE IN DRG DNMT3A (A DE NOVO DNMT) RESCUED THE EXPRESSION OF OPRM1 AND OPRK1 MRNAS AND THEIR RESPECTIVE ENCODING MU-OPIOID RECEPTOR (MOR) AND KAPPA-OPIOID RECEPTOR (KOR) PROTEINS IN THE INJURED DRG. BLOCKING THIS INCREASE ALSO PREVENTED THE NERVE INJURY-INDUCED INCREASE IN DNA METHYLATION IN THE PROMOTER AND 5'-UNTRANSLATED REGION OF THE OPRM1 GENE IN THE INJURED DRG, RESTORED MORPHINE OR LOPERAMIDE (A PERIPHERAL ACTING MOR PREFERRING AGONIST) ANALGESIC EFFECTS, AND ATTENUATED THE DEVELOPMENT OF THEIR ANALGESIC TOLERANCE UNDER NEUROPATHIC PAIN CONDITIONS. MIMICKING THIS INCREASE REDUCED THE EXPRESSION OF OPRM1 AND OPRK1 MRNAS AND THEIR CODING MOR AND KOR IN DRG AND AUGMENTED MOR-GATED NEUROTRANSMITTER RELEASE FROM THE PRIMARY AFFERENTS. MECHANISTICALLY, DNMT3A REGULATION OF OPRM1 GENE EXPRESSION REQUIRED THE METHYL-CPG-BINDING PROTEIN 1, MBD1, AS MBD1 KNOCKOUT RESULTED IN THE DECREASED BINDING OF DNMT3A TO THE OPRM1 GENE PROMOTER AND BLOCKED THE DNMT3A-TRIGGERED REPRESSION OF OPRM1 GENE EXPRESSION IN DRG NEURONS. THESE DATA SUGGEST THAT DNMT3A IS REQUIRED FOR NERVE INJURY-INDUCED AND MBD1-MEDIATED EPIGENETIC SILENCING OF THE MOR AND KOR IN THE INJURED DRG. DNMT3A INHIBITION MAY SERVE AS A PROMISING ADJUVANT THERAPY FOR OPIOID USE IN NEUROPATHIC PAIN MANAGEMENT. 2017 20 2407 30 EPIGENETIC RESTORATION OF VOLTAGE-GATED POTASSIUM CHANNEL KV1.2 ALLEVIATES NERVE INJURY-INDUCED NEUROPATHIC PAIN. VOLTAGE-GATED POTASSIUM CHANNELS (KV) ARE IMPORTANT REGULATORS OF NEURONAL EXCITABILITY FOR ITS ROLE OF REGULATING RESTING MEMBRANE POTENTIAL AND REPOLARIZATION. RECENT STUDIES SHOW THAT KV CHANNELS PARTICIPATE IN NEUROPATHIC PAIN, BUT THE DETAILED UNDERLYING MECHANISMS ARE FAR FROM BEING CLEAR. IN THIS STUDY, WE USED SIRNA, MIR-137 AGOMIR, AND ANTAGOMIR TO REGULATE THE EXPRESSION OF KV1.2 IN SPINAL CORD AND DORSAL ROOT GANGLIA (DRG) OF NAIVE AND CHRONIC CONSTRICTION INJURY (CCI) RATS. KV CURRENTS AND NEURON EXCITABILITY IN DRG NEURONS WERE EXAMINED BY PATCH-CLAMP WHOLE-CELL RECORDING TO VERIFY THE CHANGE IN KV1.2 FUNCTION. THE RESULTS SHOWED THAT KV1.2 WAS DOWN-REGULATED IN DRG AND SPINAL DORSAL HORN (SDH) BY CCI. KNOCKDOWN OF KV1.2 BY INTRATHECALLY INJECTING KCNA2 SIRNA INDUCED SIGNIFICANT MECHANICAL AND THERMAL HYPERSENSITIVITY IN NAIVE RATS. CONCOMITANT WITH THE DOWN-REGULATION OF KV1.2 WAS AN INCREASE IN THE EXPRESSION OF THE MIR-137. THE TARGETING AND REGULATING OF MIR-137 ON KCNA2 WAS VERIFIED BY DUAL-LUCIFERASE REPORTER SYSTEM AND INTRATHECAL INJECTING MIR-137 AGOMIR. FURTHERMORE, RESCUING THE EXPRESSION OF KV1.2 IN CCI RATS, ACHIEVED THROUGH INHIBITING MIR-137, RESTORED THE ABNORMAL KV CURRENTS AND EXCITABILITY IN DRG NEURONS, AND ALLEVIATED MECHANICAL ALLODYNIA AND THERMAL HYPERALGESIA. THESE RESULTS INDICATE THAT THE MIR-137-MEDIATED KV1.2 IMPAIRMENT IS A CRUCIAL ETIOPATHOGENESIS FOR THE NERVE INJURY-INDUCED NEUROPATHIC PAIN AND CAN BE A NOVEL POTENTIAL THERAPEUTIC TARGET FOR NEUROPATHIC PAIN MANAGEMENT. 2021